Enanta Pharmaceuticals Reports Q1 Loss

Biotech firm sees $11.9 million deficit in latest quarter

Published on Feb. 9, 2026

Got story updates? Submit your updates here. ›

Enanta Pharmaceuticals, a biotech company based in Watertown, Massachusetts, reported a loss of $11.9 million in its fiscal first quarter.

Why it matters

Enanta Pharmaceuticals is a publicly traded biopharmaceutical company focused on developing treatments for viral infections and liver diseases. Its quarterly financial results are closely watched by investors and analysts as indicators of the company's performance and future prospects.

The details

The company did not provide additional details about the factors contributing to the Q1 loss in its brief earnings announcement. Enanta is best known for its work on hepatitis C treatments, though it has a broader pipeline of drug candidates targeting other viral infections.

  • Enanta Pharmaceuticals reported its fiscal Q1 2026 results on February 9, 2026.

The players

Enanta Pharmaceuticals Inc.

A publicly traded biopharmaceutical company focused on developing treatments for viral infections and liver diseases.

Got photos? Submit your photos here. ›

The takeaway

Enanta's Q1 loss raises questions about the company's financial performance and the status of its drug development pipeline, which investors will be watching closely in the quarters ahead.